- Zoetis Inc., headquartered in Parsippany, New Jersey, is the world's leading animal health company, specializing in the development and commercialization of veterinary pharmaceuticals and vaccines.
- In its fourth quarter of 2025, Zoetis reported a revenue of $2.4 billion, reflecting a 3% growth, and an adjusted net income of $648 million, demonstrating a 4% organic operational growth.
- The company serves a diverse customer base, including veterinarians, livestock producers, and pet owners, and has established partnerships that enhance its product offerings and market reach.
- Sales teams should focus on Zoetis now as they anticipate a revenue guidance of $9.825 - $10.025 billion for 2026, indicating a strong market demand for their solutions in animal health management.
Zoetis maintains a diverse departmental structure with a total of 19 departments. The largest department, Operations, employs 1,373 individuals, followed by Information Technology with 699 employees and Community and Social Services housing 598 staff members. This distribution indicates a strong emphasis on operational efficiency and technological support, alongside a commitment to community engagement. The balance across departments suggests a well-rounded workforce capable of addressing various aspects of the pharmaceutical industry.
The geographic distribution of Zoetis's workforce spans 455 locations, with significant concentrations in key areas. Madison, NJ, leads with 540 employees, followed by Kalamazoo, MI, with 325 and Parsippany, NJ, housing 303 staff members. The presence of a large 'Other' category, accounting for 4,309 employees, indicates a distributed workforce model, allowing for flexibility and regional responsiveness. This distribution reflects both strategic local operations and a broad national footprint.
